

FROM COMPLIANCE TO QUALITY EXCELLENCE: NAVIGATING THE 13 PARTS OF INDIA'S REVISED SCHEDULE M UNDER UPDATED CDSCO GMP GUIDELINES

Keshiha Chauhan^{1*}, Dr. Nidhi Chauhan³, Poonam Sonawane², Mohammad Naimuddin Chauhan¹, Singh Mohit Awadhesh¹, Sagar Dixit Kumar Kaushikbhai¹

¹M Pharm (Pharmaceutical Quality Assurance) Student, Laxminarayan Dev College of Pharmacy, Bholav, Bharuch, 392015.

²M Pharm (Pharmaceutics) Student, Laxminarayan Dev College of Pharmacy, Bholav, Bharuch, 392015.

³M Pharm (Pharmaceutical Quality Assurance) Principal, Laxminarayan Dev College of Pharmacy, Bholav, Bharuch, 392015.

Article Info: Received: 11 July 2026, Revised: 31 July 2026, Accepted: 21 August 2026

***Corresponding Author: Keshiha Chauhan**

M Pharm (Pharmaceutical Quality Assurance) Student, Laxminarayan Dev College of Pharmacy, Bholav, Bharuch, 392015.

DOI: <https://doi.org/10.5281/zenodo.22211260>



Citation:

Keshiha Chauhan^{1*}, Dr. Nidhi Chauhan³, Poonam Sonawane², Mohammad Naimuddin Chauhan¹, Singh Mohit Awadhesh¹, Sagar Dixit Kumar Kaushikbhai¹. (2026). From Compliance To Quality Excellence: Navigating The 13 Parts Of India's Revised Schedule M Under Updated Cdsco Gmp Guidelines. International Journal of Clinical and Pharmaceutical Innovations, 1(6), 33-42.

ABSTRACT

Good Manufacturing Practices play a critical role in ensuring that pharmaceutical products are manufactured consistently and meet required standards, safety, efficacy, and quality. In India, these standards are regulated through Schedule M of the Drugs and Cosmetics Rules, which establishes guidelines for pharmaceutical manufacturing facilities, quality systems, documentation practices, and regulatory compliance. The recently revised Schedule M introduces a stronger focus on the Pharmaceutical Quality System, risk management, validation, and continuous quality improvement to align Indian manufacturing practices with global GMP expectations. This review article explores the structure and significance of the 13 parts of the revised Schedule M and their contribution to strengthening pharmaceutical manufacturing standards in India. Particular emphasis is placed on essential GMP elements such as documentation systems, personnel training, facility design, validation, quality control, complaint handling, product recall procedures, and self-inspection mechanisms. The article also highlights the increasing role of digital technologies, including electronic documentation systems and audit trails, which support data integrity and regulatory transparency. By integrating global quality principles with national regulatory requirements, the revised Schedule M supports the development of a more robust pharmaceutical quality framework that enhances product reliability, regulatory compliance, and international acceptance of medicines manufactured in India.

KEYWORDS: GMP, Schedule M, Audit, 13 parts of GMP Regulation.

INTRODUCTION

A production and testing procedure that aids in guaranteeing a high-quality product is known as a good manufacturing practice (GMP). Nations have enacted laws requiring pharmaceutical and medical device manufacturers to adhere to GMP practices, and they have

developed their own GMP guidelines that align with these laws. The ultimate goals of protecting patient health and producing medicines of the highest quality, medical devices, or active drug products are basically similar to the fundamental concepts of all these standards. With the introduction of the FDA's current

good manufacturing practices, or cGMP, the world came together to standardize its methods and guidelines. In the twenty-first century, there has been an increasing recognition of the importance of pharmaceutical product quality.^[1] Auditing is an essential duty that is carried out to evaluate the reliability and preciseness of the data on how The business successfully handles the Caliber of its operations and output.^[2,3] An audit is generally defined as an examination of a system or process to make sure it comply with the guidelines for its intended use.^[2,4] The International Organization for Standardization (ISO) defines an audit as a "systematic, independent, and documented process for obtaining audit evidence and evaluating them objectively to determine the degree to

which the verification criteria are met."^[2,3] For marketing authorization dossiers, the pharmaceutical industry has switched from paper-based to digital documentation, highlighting the necessity of long-term or permanent record keeping and the skills needed to manage digital information.^[6,7] The process of passing on biological, chemical, or physical risks from one food product to another, thereby compromising that product's quality and safety, is known as cross-contamination.^[8,9] A qualified inspector should be a scientist, chemist, or pharmacist with expertise in manufacturing standards. experience or industrial background in the production process of pharmaceuticals and should be agreeable.^[10,11]

DRUGS & COSMETICS ACT – SCHEDULES A TO Z							
Schedule A FORMS & FORMATS Application forms, Licenses, Test reports	Schedule B STANDARD TEST PROCEDURES Testing methods for drugs	Schedule C BIOLOGICAL PRODUCTS Vaccines, Sera, Toxins, Insulin	Schedule H STRICT PRESCRIPTION Must carry "Caution: Medical, Narcotics"	Schedule M1 DISINFECTANT FLUIDS Standards for disinfectants	Schedule M2 GMP - COSMETICS Standards for cosmetic units		
Schedule C1 SPECIAL BIOLOGICS Antibiotics, Vitamins by injection	Schedule D EXEMPTED DRUGS List of exempted drugs for import	Schedule E1 POISONOUS SUBSTANCES Atropine, Ergot, Digitalis	Schedule I PROPRIETARY MEDICINES Standards for proprietary medicines (Rare)	Schedule P SHELF-LIFE Minimum shelf-life & Expiry norms	Schedule P1 SPECIAL STORAGE Cold storage, specific conditions		
Schedule F BLOOD BANKS Standards for blood & products	Schedule F1 VACCINES/ANTISERA Standards for vaccines, sera	Schedule G PRESCRIPTION-ONLY Must carry "Caution: Medical Advice"	Schedule O DISINFECTANT FLUIDS Standards for disinfectants	Schedule Q MEDICAL DEVICES (Older) Requirements & Standards	Schedule R1 MDR 2017 Medical Devices Regulation		
Schedule H STRICT PRESCRIPTION Antibiotics, Antipsychotics, Narcotics	Schedule H1 HIGH-SURVEILLANCE 3rd/4th Gen Antibiotics, Anti-TB	Schedule M GMP Good Manufacturing Practices for Pharmaceuticals	Schedule S COSMETICS STANDARDS Standards for finished cosmetics	Schedule T GMP - AYUSH Good Manufacturing Practices (Ayurveda, Siddha, Unani)	Schedule U RECORD KEEPING Manufacturing records & documentation		
Schedule J PROPRIETARY MEDICINES Standards for proprietary medicine	Schedule M2 GMP - COSMETICS Standards for cosmetic units	Schedule P1 SPECIAL STORAGE Cold storage, specific conditions	Schedule U1 CLINICAL TRIALS DOCS Trial documentation requirements	Schedule V PATENT MEDICINES Standards for patent/proprietary drugs	Schedule W RETAIL SALES ONLY List of retail-only drugs (Rare)		
Schedule J UNCURABLE DISEASES Cannot claim to cure (Cancer, AIDS)	Schedule K EXEMPTION RULES Antiseptics, Disinfectants	Schedule N RETAIL PHARMACY Requirements (Area, Equipment)	Schedule X NARCOTICS/ PSYCHOTROPICS Restricted drugs (e.g., Benzodiazepines)	Schedule Y CLINICAL TRIALS & NEW DRUGS Approval process for new drugs	Schedule Z PHARMACOVIGILANCE Safety monitoring of drugs		

Fig No. 1: A TO Z SCHEDULES.

Regulatory Framework in India

The Indian pharmaceutical business is well recognized as one of the largest producers of generic drugs, offering affordable, high-quality drugs to more than 200 countries. India's regulatory framework has continuously evolved to meet international standards in order to protect its standing overseas and ensure patient security. A significant amount of this regulatory environment is governed by Schedule M of the Drugs and Cosmetics Rules, 1945, which sets criteria for Good Manufacturing Practices (GMP) and facilities for pharmaceutical manufacturing.^[12] In the pharmaceutical industry, regulatory refers to the laws, rules, guidelines, and processes established by national and international authorities to ensure that pharmaceuticals are safe, effective, and of the highest Caliber prior to their administration to patients. Every phase of the medicine lifecycle, from development to marketing and post-marketing monitoring, requires pharmaceutical companies to abide by this set of guidelines and compliance requirements.^[13]

SCHEDULE M

Schedule M, which is a component of the 1945 Drugs & Cosmetics Rules under the 1940 Drugs & Cosmetics Act, outlines the facilities, machinery, and equipment required for the Indian pharmaceutical industry as well as the Good Manufacturing Practices (GMP) standards. In other words, it sets the minimal standards for quality that all pharmaceutical producers must adhere to in order to ensure that their products are safe, effective, and of consistent quality. It outlines the Good Manufacturing Practices (GMP) requirements as well as the facilities, machinery, and equipment required for the Indian pharmaceutical industry. In short, it sets the minimal standards for quality that every pharmaceutical, to ensure that their products are reliable, safe, and of consistent quality, manufacturers must comply.^[14] to ensure uniform quality standards in the pharmaceutical manufacturing sector in India.

To ensure that Indian production complies with international GMP requirements. To provide guidelines for staff, facilities, equipment, documentation, and

quality assurance. To lower the risk of contamination, miscommunication, and errors to safeguard public health.^[13]

Increases the acceptability of Indian medications in international markets; ensures similar standards across states, preventing quality differences; and provides the legal basis for GMP in India. Prevents disparities in quality by guaranteeing consistent standards across states. The acceptance of Indian pharmaceuticals in international markets has increased.^[13]

HISTORY

The Good Manufacturing section of the Drugs and Cosmetics Act 1940 first appeared in Schedule M of the Drugs and Cosmetics Act & Rules in 1988, and the most recent modification was made in June 2005. It addresses the Good Manufacturing Practices for pharmaceuticals that Indian pharmaceutical manufacturing facilities must adhere to. The 1988 regulations, which were last amended in June 2005, address the Good Manufacturing Practices for medicines that Indian pharmaceutical manufacturing facilities must adhere to.^[14,15,16]

The revised schedule M, which primarily focuses on the quality management system of the pharmaceutical product, was put into effect on December 28, 2023. Schedule M guides on Good Manufacturing Practices regarding company premises, quality control system, quality check laboratories, production, cleaning of equipment, housekeeping, cross-contamination, and other related topics.^[14]

corporate facilities, quality control systems, quality check labs, manufacturing, equipment cleaning, housekeeping, cross-contamination, and other associated subjects. The updated schedule M, which primarily focuses on the pharmaceutical product's quality management system, was put into effect on December 28, 2023.^[14,17]

OLD SCHEDULE M

Schedule M was first divided into 2 parts:

Part 1

Good Manufacturing practices for the premises and materials.

It also had a subpart starting from 1A to 1F.

Part 2

External Preparations.

Oral Liquid Preparations

Tablets

Powders

Capsule

Surgical Dressing

Ophthalmic Preparations

Pressurizes and suppositories

Inhalers

Repacking of Drugs and Pharmaceutical Chemicals

Parenteral Preparation

Part 1

Good Manufacturing Practices for Pharmaceutical Products.

Part 1 is completely different.

This Part 1 is termed as —Main Principlesl & it is mandatory to follow irrespective of product category.

An Appendix I which deals with requirements of Site Master File.

Part 2 to Part 12

Specified requirements for manufacturing, as per product categories. E.g. Sterile products.

Oral Solid dosage Forms etc.

Five new categories are added as compared to existing Schedule M.

Part 13

Requirements of plant and equipment for manufacturing of 11 categories of pharma products.

This section is similar as of previous schedule M 2001.

New Schedule M

Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products.

Part 1

Pharmaceutical Quality system

Quality Risk Management

Good Manufacturing practice for pharmaceutical products.

Sanitation and Hygiene practices

Qualification and Validation.

Complaints and Adverse Reaction

Product Recall

Change Control

Production under loan license or contract and contract analysis and other activities.

Self-inspection, quality audits and supplier audits and approval

Personnel

Premises

Equipment

Materials

Reference standards

Waste materials.

Documentation

Good practices in production

Good practices in quality control

Computerized system

Part 2 to Part 12

Part 2- Specific requirements for manufacture of Sterile Products, Small & Large Volume Parentals, Ophthalmic Preparations.

Part 3 Specific requirements for manufacture of Hazardous substances such as Sex Hormones, Steroids or Cytotoxic substances (Newly Added).

Part 4 Specific requirements for manufacture of Biological Products (Newly Added).

Part 5 Specific requirements for manufacture of Radiopharmaceutical Products (Newly Added).

Part 6 Specific requirements for manufacture of Phytopharmaceutical Products (Newly Added).

Part 7 Specific requirements for manufacture of Investigational Pharmaceutical Products for Clinical Trials in Human (Newly Added).

Part 8 Specific requirements for manufacture of Oral Solid Dosage Forms.

Part 9 Specific requirements for manufacture of Oral Liquids.

Part 10 Specific requirements for manufacture of External Preparations.

Part 11 Specific requirements for manufacture of Metered Dose-Inhalers.

Part 12 Specific requirements for manufacture of Active Pharmaceutical Ingredient.

2. Requirements of Plant and Equipment for Oral Liquid Preparations.

3. Requirements of Plant and Equipment for Tablets.

4. Requirements of Plant and Equipment for Powders.

5. Requirements of Plant and Equipment for Capsules.

6. Requirements of Plant and Equipment for Surgical Dressing.

7. Requirements of Plant and Equipment for Ophthalmic Preparations.

8. Requirements of Plant and Equipment for Pessaries and Suppositories.

9. Requirements of Plant and Equipment for Inhalers and Vitalie.

10. Requirements of Plant and Equipment for Repacking of Drugs and Pharmaceutical Chemicals.

11. Requirements of Plant and Equipment for Parental Preparation.

Part 13

1. Requirements of Plant and Equipment for External Preparations.

Table No. 1: Comparison Table of Old Schedule M and Revised Schedule M.

Aspect	Old Schedule M	Revised Schedule M
Regulatory Objective	Focused mainly on minimum GMP compliance requirements for pharmaceutical manufacturing.	Emphasizes a comprehensive pharmaceutical quality system and continuous quality improvement aligned with international GMP standards.
Global Alignment	Limited alignment with global regulatory frameworks.	Harmonized with guidelines from the World Health Organization and Pharmaceutical Inspection Co-operation Scheme to support international regulatory expectations.
Quality Management System	Quality management principles were mentioned but not structured as an integrated system.	Introduces a formal Pharmaceutical Quality System (PQS) with defined responsibilities, quality policies, and continuous monitoring.
Quality Risk Management	Risk-based approaches were not clearly defined.	Strong emphasis on risk assessment and mitigation strategies throughout the manufacturing process.
Documentation Practices	Paper-based documentation was primarily used, with limited guidance on data governance.	Strengthens documentation requirements and promotes data integrity and controlled electronic documentation systems.
Personnel Training	General training requirements were mentioned without structured competency evaluation.	Requires systematic training programs, competency assessment, and clear documentation of personnel qualifications.
Facility and Equipment Requirements	Provided basic requirements for premises and equipment layout.	Includes detailed expectations for facility design, contamination control, equipment qualification, and environmental monitoring.
Validation and Qualification	Validation activities were mentioned but with limited lifecycle guidance.	Introduces lifecycle-based validation approaches including equipment qualification (IQ, OQ, PQ), process validation, and cleaning validation.
Change Control System	Change management was not clearly defined.	Establishes formal change control procedures to evaluate and approve modifications affecting product quality.
Complaint Handling and Product Recall	Complaint handling procedures existed but were less structured.	Provides detailed systems for complaint investigation, root cause analysis, and product recall management.
Self-Inspection and Audits	Internal inspections were recommended but lacked systematic	Requires structured self-inspection programs and periodic GMP audits to ensure

	frameworks.	compliance.
Contract Manufacturing and Analysis	Limited regulatory guidance on outsourcing activities.	Provides clear requirements for vendor qualification, quality agreements, and oversight of contract manufacturing and testing.
Technology Transfer	Not explicitly addressed.	Introduces detailed provisions for technology transfer between manufacturing sites to ensure process consistency and quality control.

THE 13 PARTS OF INDIA'S REVISED SCHEDULE M

1) Pharmaceutical Quality System (PQS)

It is an element of the pharmaceutical industry's pharmaceutical management system. Pharmaceutical excellence system should be used for the product from the time it is manufactured until it is shipped to the market.^[13,18] It is the responsibility of senior management in every manufacturing organization to develop an efficient PQS in the company. Only once the final product has been inspected and verified can it be dispatched. Corrective action and preventative action, or CAPA, should be upheld so that any issues with the product can be found through root cause analysis and prevented from occurring repeatedly.^[15,19] The Pharmaceutical Quality Management System (QMS) tries to provide and maintain exceptional and consistent quality in the manufacturing of pharmaceuticals using a comprehensive set of rules, procedures, and methods.^[15,20]

2) Personnel

Strict hygienic and sanitary regulations must be complied to in every aspect of the manufacturing process for pharmaceuticals. Workers, facilities, containers, equipment, production materials, and cleaning and disinfecting supplies should all be included in the scope of hygiene and sanitation. Everything that comes into contact with the goods.^[19] Any possible sources of contamination must be eliminate, A sanitization and hygiene program ought to be implemented in position. Use soap and water to wash your hands.^[21,22]

The product could become contaminated if the clothing isn't clean. The staff members who are engaged in the manufacturing sector ought to be disease-free.^[22]

3) Premises and Equipment

The revised Schedule M under the Central Drugs Standard Control Organization emphasizes that pharmaceutical premises and equipment should be scientifically designed and maintained to ensure product quality, safety, and prevention of contamination during manufacturing operations. Facility design must support a logical flow of materials and personnel, with adequate space, proper segregation of production areas, controlled environmental conditions, and effective sanitation systems to minimize cross-contamination and operational errors.^[23]

4) Documentation

In the pharmaceutical industry, documentation plays a number of vital roles in the quality management system. In its most fundamental form, documentation offers the Evidentiary trail demonstrating that all manufacturing processes adhere to authorized protocols and legal standards. This evidence trail, also known as an audit trail, enables investigators to piece together the whole history of any batch, from the arrival of raw materials to the distribution of the finished product, including all processing stages, environmental factors, and quality control testing carried out during the process.^[24,25,26] Types of documentation in GMP facilities like: Quality Manuals, MFR, SOPs, BPR, Supporting records, Quality Control and Analytical Records, MPCR, etc.

Digital Documentation

21 CFR Part 11- (US FDA): In regulated businesses, this FDA rule specifies the circumstances in which electronic documents and signatures are regarded as legitimate as their paper counterparts. Systems must be appropriately validated to ensure accuracy and consistency. performance, uphold traceable and uniquely assigned electronic signatures, and keep safe audit trails that monitor user actions and timestamps. Strict access restrictions and regular system inspections are also required to safeguard data integrity and stop illegal access.^[29,30] The validity, reliability, and conformance of electronic documents and signatures to those of paper documents are guaranteed by 21 CFR Part 11 (FDA).^[29,30,31]

5) Production and In-Process Control

IPQC tests are carried out often (usually every hour) throughout the manufacturing process, Observing and, if required, altering the IPQC's objectives for specification compliance include the production process. The control of the environment or the equipment may also be a part of in-process control (IPC), The quality of the product shouldn't put them in danger. Finding problems is made easier by in-process testing. Sometimes it reveals a batch of faulty goods that could be reworked, Once that batch is finished, this might not be feasible. If the product didn't meet IPC specifications, it's probable that certain variables were out of control or that such processes weren't followed. The pharmaceutical industry should develop SOPs, or standard operating procedures, as well as procedures that define and test IPQC.^[27,28]



Fig No. 2: 13 PARTS OF SCHEDULE M.

6) Quality Control

GMP handles both production and quality control.^[33,34] In order to remove errors at every level of production, quality control (QC) specialists evaluate the quality of all production-related aspects as part of GMP. By preventing or removing faults at every stage of manufacturing, quality control aims to create a flawless final product. QC is a collaborative effort, and we must keep in mind that quality must be incorporated into a pharmaceutical product throughout product and process design. It is impacted by the physical plant design, space, ventilation, cleanliness, and sanitation during regular production.^[33,35] The Central Drugs Standard Control Organization's updated Schedule M enhances the function of Quality Control (QC) in ensuring that pharmaceutical goods consistently fulfil predetermined standards for efficacy, safety, and quality throughout the production process.^[36]

7) Qualification and Validation

More specific needs are listed in the revised schedule M than in the old one. The tools, standardized equipment, It

helps to identify the processes and procedures that the organization wants qualified and validated. A validation master plan that defines the key components of the validation and qualification program should be in place.^[15,37] It is important to clearly define who is responsible for carrying out validation operations. Particular attention needs to be devoted to cleaning techniques, analytical test procedures, and automated system validation. Additionally, it is important to the product's manufacture.^[15,38] Validation makes it possible to verify that pharmaceutical manufacturing processes, equipment, and computerized systems are used to ensure that pharmaceutical products can meet the necessary quality standards. Qualification of different utilities, facilities, and equipment, including installation qualification, Pharmaceuticals validation procedures are said to need both operational and performance qualification.^[39-41]

8) Complaints and Product Recall

Handling of product complaints and the implementation of an effective recall system are essential elements of

Good Manufacturing Practices (GMP) in pharmaceutical manufacturing. According to Schedule M of the Drugs and Cosmetics Rules, manufacturers must establish a well-defined procedure for receiving, recording, investigating, and responding to complaints related to the quality, safety, or performance of pharmaceutical products. Product recall is another critical component of GMP that ensures defective or potentially harmful pharmaceutical products are quickly removed from the market. A recall may be initiated when a product is found to be substandard, contaminated, mislabelled, or otherwise not in compliance with regulatory specifications.^[36]

9) Self-inspection / Quality Audit

As regulatory organizations enhance their control to guarantee ongoing GMP compliance, regulatory inspections of pharmaceutical production plants have also increased in frequency and intensity. Manufacturers are expected to show regular and regular compliance to regulatory requirements instead of rather than temporary compliance in order to prepare for an inspection.^[39,43]

audit is a “systematic, independent, and documented process for obtaining audit evidence and evaluating them objectively to determine the degree to which the verification criteria are met.”^[44,45] Types of Audits: Internal Audit, External Audits, Regulatory Audits:

Internal audits, also referred to as self-audits or first-party audits, are carried out within the framework of an organization. The auditees and the auditors are participants in the same organization.^[46,47] Internal audits are used to evaluate organizational problems and progressively find solutions. Generally, the company's owner or management receives reports from the internal audit.^[45,47]

An organization conducts external audits, also referred to as second-party audits, on its suppliers or subcontractors. These audits are conducted to evaluate suppliers' compliance to quality system specifications and make sure the goods or services received are always of high quality, but they are not legally required. To make sure that companies follow regulations, regulatory audits are essential. They support regulatory agencies in evaluating manufacturing procedures, quality systems, safety, efficacy, and product quality.^[47,48]

Table No. 2: Comparision Table.

Requirement	FDA 21 CFR Part 11	EU Annex 11	Implementation Approach
Audit Trail Capture	Must record date, time, user ID for all changes	Must track critical data changes	Comprehensive logging for all critical operations
Time Stamping	Computer-generated timestamps required	Time stamps must be accurate	Synchronized time servers across all systems
User Authentication	Electronic signatures required	Authorized user access only	Integrated identity management system
Data Integrity	ALCOA principles	Data should be complete and accurate	Automated validation rules and checks
Review Requirements	Regular review of records	Periodic review of audit trails	Risk-based review frequency
Retention Period	Same as associated records	Throughout required retention	20+ years for GMP records
Security	Tamper-evident and secure	Protection against unauthorized access	Cryptographic controls and access logging

10) Contract Manufacturing and Analysis

The most significant additions to Schedule M. To prevent quality issues, activities performed under a specific arrangement and covered by GMP should be clearly defined, approved, and strictly regulated. Supply chain, technology transfer, subcontracting validation, and batch release should all be included in a high-quality contract or agreement. authority, modifications brought about by mistakes or occurrences, quality assurance, in-process controls, etc.^[21,22] contract manufacturing and contract analysis to ensure that outsourced pharmaceutical activities maintain the same quality and GMP standards as in-house operations. The contract giver and contract acceptor must clearly define their responsibilities through written quality agreements covering manufacturing processes, testing procedures, documentation, and product release activities.^[50]

11) Materials Management

Materials management to maintain the quality and safety of pharmaceutical products throughout manufacturing and distribution. Raw material handling procedures must ensure correct identification, sampling, testing, labelling, and segregation of materials to prevent contamination and mix-ups. The guidelines also require suitable storage conditions such as controlled temperature, humidity, and cleanliness to preserve material quality and stability. In addition, proper distribution practices, including documentation, stock rotation, and transportation controls, are necessary to ensure traceability and maintain product integrity until the products reach the end user.^[49]

12) Change Control

In order to prevent any negative effects on product quality or regulatory requirements, any modifications to materials, manufacturing processes, equipment, utilities, or facilities must be managed and approved through an efficient change control system. Maintenance is made easier by an efficient change control system of verified status in relation to the evaluation of possible hazards connected to such modifications.^[39,51,52,53]

13) Technology Transfer

Task assignments and responsibilities should be recorded at every stage of the process, from R&D to production, and should be generally understood as a document identifying the contents of technology and transferred parties, defined the requirements for completing the technology transfer process with regard to the specific technology that needs to be transferred. The quality assurance department is responsible for reviewing and approving the paperwork for all technology transfer procedures.^[54]

CONCLUSION

The revised GMP requirements under Schedule M of the Drugs and Cosmetics Rules represent a significant advancement in strengthening pharmaceutical manufacturing standards in India. The updated framework introduces a comprehensive Pharmaceutical Quality System that emphasizes risk-based approaches, validation, proper documentation, and continuous quality improvement throughout the product lifecycle. By incorporating detailed guidelines across thirteen structured parts, the revised Schedule M ensures that pharmaceutical manufacturers maintain consistent product quality, prevent contamination, and improve operational efficiency. Key components such as qualification and validation, complaint management, product recall systems, quality audits, and change control mechanisms contribute to maintaining regulatory compliance and protecting patient safety. Furthermore, the integration of modern digital documentation systems and electronic audit trails supports data integrity and transparency in manufacturing operations. Overall, the revised Schedule M promotes a shift from basic regulatory compliance toward a proactive quality culture within pharmaceutical organizations. This transformation not only strengthens domestic regulatory oversight but also enhances the global credibility and competitiveness of the Indian pharmaceutical industry.

REFERENCES

- Wasiullah M, Yadav P, Yadav P, Deepak VK. A review on role of GMP in pharmaceutical industry and their benefits. *World Journal of Pharmaceutical Research*, 2022 Nov 12; 12(1): 298-311.
- Alili Idrizi E, Ahmeti Lika S, Bexheti D, Dauti M, Janevik-Ivanovska E. Quality Audits-Viewpoints of Auditing in the Pharmaceutical Industry. *The Albanian Journal of Medical and Health Sciences*, 2022; 60: 1-2.
- Kumar S, Tanwar D, Arora N. The role of regulatory GMP audit in pharmaceutical companies. *Int J Res Dev Pharm Life Sci.*, 2013; 2: 493-8.
- Kaur J. Quality audit: Introduction, types and procedure. Place Unknown: Pharma Pathway; 2017. Available from: <http://pharmapathway.com/quality-audit-introduction-types-and-procedure/>.
- Biswas P. ISO 9001. Internal audit [Internet]. Place Unknown: Word Press; 2015. Available from: http://isoconsultantpune.com/iso_90012015-internal-auditby-pretesh-biswas-apb_consultant/.
- Chingale ND, Walunj SD, Kikale MS, Devade OA, Redasani V. DOCUMENTATION ESSENTIALS IN THE PHARMACEUTICAL INDUSTRY: A REGULATORY PERSPECTIVE.
- Nataschia Meneghetti, Pierantonio Facco, F. Bezzo. "Knowledge management in secondary pharmaceutical manufacturing by mining of data historians-A proof-of-concept study." *International Journal of Pharmaceutics*, Volume, 2016; 505, 1-2: 394-408.
- Kurniawan MA, Khairullah AR, Puspitasari Y, Nifa FH, Ahmad RZ, Pratama BP, Tyasningsih W, Kurniasih DA, Raharjo HM, Moses IB, Wardhani BW. Cross-contamination risks and hazard analysis and critical control point (HACCP) strategies in the meat industry: A Review. *Journal of Advanced Veterinary Research*, 2026 Jan 1; 16(2): 292-300.
- Possas, A., Perez-Rodriguez, F., 2023. New Insights into Cross-Contamination of Fresh-Produce. *Curr. Opin. Food Sci.*, 49: 100954. doi: 10.1016/j.cofs.2022.100954.
- Shihei S, Okafor UG, Ekeocha Z, Byrn S, Clase K. Improving the outcome of GMP inspections by improving proficiency of inspectors through consistent GMP trainings.
- Tomić, S., Sučić, A., & Martinac, A. (2010). Good manufacturing practice: The role of local manufacturers and competent authorities. *Archives of Industrial Hygiene and Toxicology*, 61(4): 425–436.
- Madanayake SN, Manipura A, Thakuria R and Adasooriya NM: Opportunities and challenges in mechanochemical cocrystallization toward scaled-up pharmaceutical manufacturing. *Organic Process Research & Development*, 2023; 27(3): 409-22.
- Dey S, Dutta S and Ray J: A review article on an existing schedule m vs revised schedule M. *Int J Pharm Sci & Res.*, 2025; 16(3): 663-69. doi: 10.13040/IJPSR.0975- 8232.16(3).663-69.
- Mishra L and Kurmi BD: Cosmetics regulations and standardization guidelines. *Pharmaspire*, 2023; 15: 137 50.
- Dey S, Dutta S, Ray J. A REVIEW ARTICLE ON AN EXISTING SCHEDULE M VS REVISED SCHEDULE M.
- Suamte L, Tirkey A, Barman J and Babu PJ: Various manufacturing methods and ideal properties of scaffolds for tissue engineering applications. *Smart Materials in Manufacturing*, 2023; 1: 100011.

17. Pocatilu P and Vetrici M: Schedule risk management for business M-applications development projects. WSEAS Transactions on Computers, 2009; 8(4): 735-45. 11.
18. Weaver E, O'Hagan C and Lamprou DA: The sustainability of emerging technologies for use in pharmaceutical manufacturing. Expert Opinion on Drug Delivery, 2022; 19(7): 861-72.
19. Souto EB, Silva GF, Dias-Ferreira J, Zielinska A, Ventura F, Durazzo A, Lucarini M, Novellino E and Santini A: Nanopharmaceutics: Part I—Clinical trials legislation and good manufacturing practices (GMP) of nanotherapeutics in the EU. Pharmaceutics, 2020; 12(2): 146.
20. Barshikar R: Covid 19—Impact and new normal for pharmaceutical industry (Part-I). Journal of Generic Medicines, 2020; 16(3): 112-9.
21. Weaver, Edward, Collette O'Hagan, and Dimitrios A. Lamprou. "The sustainability of emerging technologies for use in pharmaceutical manufacturing." *Expert Opinion on Drug Delivery*, 2022; 19(7): 861-872.
22. Weaver E, O'Hagan C and Lamprou DA: The sustainability of emerging technologies for use in pharmaceutical manufacturing. Expert Opinion on Drug Delivery, 2022; 19(7): 861-72.
23. Central Drugs Standard Control Organization. *Revised Schedule M under Drugs and Cosmetics Rules, 1945*. Ministry of Health and Family Welfare, Government of India, 2023.
24. Gorukanti P, Jogala S, Boggula N, Makula S. Good Manufacturing Practices and Documentation in Pharmaceutical Production: A Comprehensive Review. Asian Journal of Pharmaceutical Research and Development, 2025 Dec 15; 13(6): 86-95.
25. Qualityze. Different Types of Batch Records in Pharmaceutical Industry. Quality Management Documentation Guide, 2025.
26. 10. ValGenesis. Six Best Practices for ALCOA Data Integrity Success. GMP Compliance Blog, 2024.
27. Patil SD, Raut MK, Rathod NP. Quality Control And Quality Assurance In Pharmaceuticals. Int. J. in Pharm. Sci., 2023; 1: 91.
28. Pooja Rajan, P. Sindhuja, M. V. Nagabhushanam, Brahmaiah Bonthagarala, D. Nagarjuna Reddy and G. Ramakrishna; A Review on In processes and Finished Products Quality Control Test for tablets according to Pharmacopoeias; World Journal of Pharmacy and Pharmaceutical Sciences; page no.306 – 307.
29. Aher SN, Sonawane GB, Sonawane VN, Gunjal PA, Bacchav JB. DIGITAL DOCUMENTATION IN MODERN PHARMACEUTICAL QUALITY ASSURANCE: A STRATEGIC REVIEW. Pharmaceutical Research, 14(22): 58-72.
30. Mazan KD. FDA's Electronic Records and Electronic Signatures Rule: Structuring a Risk-Based Approach. FDLI Update, 2003; 12.
31. Burcham RL. INTRODUCTION TO FDA 21 CFR PART 11. The Pharmaceutical Regulatory Process, 2008 Dec 2; 429. 24.
32. U.S. Food and Drug Administration. 21 CFR Part 11 – Electronic Records; Electronic Signatures. Silver Spring (MD): FDA, 2003.
33. Bchkol DH, Abdulkareem AH, Habib FA. A Study on Quality Control Tests for Dosage Forms and their Effect on Physical, Chemical and Biological Specifications: A Review.
34. JM Fortunak1; RD Souza; AA Kulkarni; CL King; T Ellison; LSM Miranda, Antivi. Thera., 2014; 19(3): 4-6.
35. T Mehmood; MR Salaria; GM Herani; MA Qureshi, Ind. J. of Manage. & Soci. Sci., 2009; 3(2): 21-30.
36. <https://drugscontrol.py.gov.in/sites/default/files/2024-08/G.S.R.%20922%28E%29.pdf>
37. Becker J, Manske C and Randl S: Green chemistry and sustainability metrics in the pharmaceutical manufacturing sector. Current Opinion in Green and Sustainable Chemistry, 2022; 33: 100562.
38. Ahmed S, Islam S, Ullah B, Biswas SK, Azad AS and Hossain S: A review article on pharmaceutical analysis of pharmaceutical industry according to pharmacopoeias. Oriental Journal of Chemistry, 2020; 36(1).
39. Kumar A, Yadav DK, Kumar M, Alam T, Subramanyam S. Good Manufacturing Practices (Gmp) And Regulatory Challenges In The Pharmaceutical Industry: A Comprehensive Review.
40. Jena S., Arjun G., Ravipati A. K., kumar D. S., Vinod K. R., David B., Industrial process validation of solid dosage forms – an overview. International Journal of Pharmaceutical Sciences Review and Research, 2010; 4(2): 145-154.
41. Singh SP, Dhaker K, Namdev A, Khinchi MP, Bhatnagar S. A Review on Process Validation. PharmaTutor., 2016; 4(12): 9–19.
42. Sharma PP. Validation in Pharmaceutical Industry. 6th ed. United Kingdom: Informa Healthcare Publication, 2016; 51-70.
43. GMP Inspections | Medicines for Human Use. (2017). HPRA. Available online at: <https://www.hpra.ie/regulation/human-medicine/manufacturers/good-manufacturing-practice> (gmp)-inspections (Accessed March 4, 2025) Google Scholar.
44. Alili Idrizi E, Ahmeti Lika S, Bexheti D, Dauti M, Janevik-Ivanovska E. Quality Audits-Viewpoints of Auditing in the Pharmaceutical Industry. The Albanian Journal of Medical and Health Sciences, 2022; 60: 1-2.
45. Biswas P. ISO 9001. Internal audit [Internet]. Place Unknown: Word Press; 2015. Available from: http://isoconsultantpune.com/iso_90012015-internal-auditby-pretesh-biswas-apb-consultant/.
46. Tawade M, Pandya S, Scholar PG. Optimizing pharmaceutical quality audits: Enhancing compliance and performance through best practices.

- Journal for New Zealand Herpetology, 2023; 12(3): 6514-22.
47. Linna A, Korhonen M, Mannermaa JP, Airaksinen M, Juppo AM. Developing a tool for the preparation of GMP audit of pharmaceutical contract manufacturer. *European Journal of Pharmaceutics and Biopharmaceutics*, 2008 Jun 1; 69(2): 786-92.
 48. Agarwal PR, Mishra AM. Pharmaceutical quality audits a review. *Int J Appl Pharm.*, 2019; 11: 14-22.
 49. <https://cdsco.gov.in/opencms/opencms/en/About-us/Introduction/>
 50. Ahmed, S, Kundu, S, Patra, R, and Ray, J. Change control from initiation to implementation in the pharmaceutical industry: a comprehensive review. *Int J Res Pharm Sci.*, 2024; 15: 21–33. doi: 10.26452/ijrps.v15i3.4681Crossref Full Text | Google Scholar
 51. Jena S., Arjun G., Ravipati A. K., kumar D. S., Vinod K. R., David B., Industrial process validation of solid dosage forms – an overview. *International Journal of Pharmaceutical Sciences Review and Research*, 2010; 4(2): 145-154.
 52. Quality Management System – Process Validation Guidance GHTF/SG3/N99-10:2004 (Edition 2)
 53. Waghmare YS, Mahaparale SP. The important role of technology transfer in pharmaceutical industry-a review. *World Journal of Pharmaceutics Research*, 2017 Jun 28; 6(9): 310-29.
 54. Ortega AJ, Arce NA, Sequeda F, Gribenchenko I. Management of Innovation and Technology transfer process between University and Industry. *The Mater Res Cent Case*, 2009; 2: 7-8.